Key Points Pfizer's 6% dividend yield is backed by a rebuilding pipeline in oncology, vaccines, and obesity treatments. Bristol Myers Squibb has raised its dividend for 17 straight years while building a next-generation drug portfolio. One offers a higher yield but greater turnaround risk, while the other offers steadier, proven growth. 10 stocks we like better than Bristol Myers Squibb › Companies like Pfizer (NYSE: PFE) and Bristol Myers Squibb (NYSE: BMY) prove that income investors don't have to give up growth potential to collect a big dividend. Both companies pair generous payouts with drug portfolios that are shifting toward the next generation of medicines. That combination makes these two stocks worth a closer look.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.